Aspirin and Preeclampsia
Recruiting · NCT04479072 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Chicago
View the official record on ClinicalTrials.gov →Interventions studied
Aspirin 81 mgPlacebo
What this trial is about
This is a single-center, double-blind, randomized, placebo-controlled clinical trial. Peripartum and postpartum Activin A are significantly elevated in women with preeclampsia. Our hypothesis is that elevated Activin A levels reflect a remediable signal and that reducing postpartum Activin A levels with aspirin therapy will improve (GLS) in preeclamptic patients.
Who can take part
Age range
18 Years to 45 Years
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Pregnant Adults between 18 and 45 years of age
- Diagnosed with preeclampsia
- Presenting for delivery with a singleton gestation.
Exclusion criteria
- We will exclude patients in labor
- Patients with preexisting cardiomyopathy, chronic hypertension, ischemic or valvular heart disease, pulmonary disease, diabetes mellitus, chronic kidney disease, multiple gestation
- Plan to deliver outside of the participating site
- Co-enrolled in other trials that might affect the patients taking the study medication, as determined by the PI.
- Aspirin allergy
- Clear indication for aspirin therapy or contraindication to aspirin therapy
- Clinically significant conditions that might limit adherence to trial regimen (e.g., peptic ulcer disease, history of gastrointestinal bleeds, bleeding disorders)
- Currently or planning on taking any nonsteroidal anti-inflammatory drugs while they are participating in this study.
- Those who cannot provide consent
Where it is running
1 location listed across 1 US state.
- University of Chicago Hospital - Chicago, Illinois, United States